FAQ: Soligenix's HyBryte™ Phase 3 FLASH2 Study Safety Review and CTCL Treatment Development
Summary
Soligenix announced that its Data Monitoring Committee completed the first safety review of the Phase 3 FLASH2 study for HyBryte™ in cutaneous T-cell lymphoma, finding no safety concerns and maintaining an acceptable safety profile consistent with prior trials. Enrollment is progressing on schedule with key milestones expected in 2025 and 2026.
What is the main announcement from Soligenix regarding HyBryte?
Soligenix announced that its Data Monitoring Committee completed its first review of the confirmatory Phase 3 FLASH2 study of HyBryte™ in cutaneous T-cell lymphoma, concluding there are no safety concerns and that the therapy maintains an acceptable safety profile consistent with prior trials.
Why is this safety review important for HyBryte development?
This positive safety review confirms that HyBryte maintains an acceptable safety profile, which is crucial for advancing the therapy through clinical trials and toward potential regulatory approval as a treatment for cutaneous T-cell lymphoma.
What is HyBryte and what condition does it treat?
HyBryte™ (synthetic hypericin) is a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease where there is an unmet medical need.
When are the next key milestones expected for the FLASH2 study?
An update on enrollment is expected in Q4 2025, and a blinded interim efficacy analysis is planned for the first half of 2026.
How does this Phase 3 FLASH2 study relate to previous research on HyBryte?
The FLASH2 trial builds on the Company’s earlier statistically significant Phase 3 results and additional supportive studies demonstrating HyBryte’s efficacy and tolerability as a potential first-line treatment option for early-stage CTCL.
What other development programs does Soligenix have beyond HyBryte?
Soligenix has development programs including synthetic hypericin expansion into psoriasis, dusquetide for inflammatory diseases including oral mucositis, and vaccine programs for ricin toxin, filoviruses, and COVID-19 using their proprietary ThermoVax® heat stabilization technology.
Where can investors find more information about Soligenix and updates?
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX, and the full press release can be viewed at https://ibn.fm/o0Xgw.
What is Soligenix’s focus as a biopharmaceutical company?
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, with business segments in Specialized BioTherapeutics and Public Health Solutions.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 245367